Heidelberg Pharma AG (HPHA.DE)
EUR 2.38
(-0.42%)
EUR 2.38
(-0.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 27.81 Million EUR | 3.35% |
| 2022 | 32.16 Million EUR | 40.9% |
| 2021 | 22.83 Million EUR | 6.43% |
| 2020 | 21.45 Million EUR | 53.95% |
| 2019 | 13.93 Million EUR | 3.09% |
| 2018 | 13.51 Million EUR | 14.66% |
| 2017 | 11.78 Million EUR | 68.8% |
| 2016 | 6.98 Million EUR | -22.15% |
| 2015 | 8.97 Million EUR | 0.14% |
| 2014 | 8.95 Million EUR | -54.42% |
| 2013 | 19.65 Million EUR | -1.77% |
| 2012 | 20 Million EUR | 4.77% |
| 2011 | 19.09 Million EUR | -17.38% |
| 2010 | 23.11 Million EUR | 1.08% |
| 2009 | 22.86 Million EUR | 6.87% |
| 2008 | 21.39 Million EUR | 231.81% |
| 2007 | -16.23 Million EUR | -52.17% |
| 2006 | -10.66 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.09 Million EUR | -17.83% |
| 2024 Q2 | 7.03 Million EUR | 15.44% |
| 2024 Q3 | 7.15 Million EUR | -0.24% |
| 2023 Q2 | 10.47 Million EUR | 44.07% |
| 2023 Q1 | 7.26 Million EUR | -25.52% |
| 2023 Q3 | 9.15 Million EUR | -12.57% |
| 2023 Q4 | 7.41 Million EUR | -19.02% |
| 2023 FY | 33.24 Million EUR | 3.35% |
| 2022 Q4 | 9.75 Million EUR | 31.94% |
| 2022 Q1 | 7.28 Million EUR | 25.33% |
| 2022 Q2 | 7.73 Million EUR | 6.17% |
| 2022 Q3 | 7.39 Million EUR | -4.34% |
| 2022 FY | 32.16 Million EUR | 40.9% |
| 2021 Q1 | 5.66 Million EUR | 9.6% |
| 2021 Q3 | 4.95 Million EUR | -22.57% |
| 2021 Q4 | 5.81 Million EUR | 17.31% |
| 2021 Q2 | 6.39 Million EUR | 12.85% |
| 2021 FY | 22.83 Million EUR | 6.43% |
| 2020 Q1 | 4.82 Million EUR | 12.08% |
| 2020 FY | 21.45 Million EUR | 53.95% |
| 2020 Q2 | 5.71 Million EUR | 18.45% |
| 2020 Q3 | 5.73 Million EUR | 0.37% |
| 2020 Q4 | 5.17 Million EUR | -9.84% |
| 2019 FY | 13.93 Million EUR | 3.09% |
| 2019 Q1 | 3.71 Million EUR | -4.99% |
| 2019 Q2 | 2.74 Million EUR | -25.91% |
| 2019 Q3 | 3.16 Million EUR | 15.21% |
| 2019 Q4 | 4.3 Million EUR | 35.92% |
| 2018 Q1 | 2.75 Million EUR | -16.21% |
| 2018 Q2 | 3.38 Million EUR | 22.95% |
| 2018 FY | 13.51 Million EUR | 14.66% |
| 2018 Q4 | 3.9 Million EUR | 12.5% |
| 2018 Q3 | 3.47 Million EUR | 2.58% |
| 2017 FY | 11.78 Million EUR | 68.8% |
| 2017 Q3 | 3.76 Million EUR | 37.46% |
| 2017 Q4 | 3.28 Million EUR | -12.74% |
| 2017 Q2 | 2.73 Million EUR | 18.58% |
| 2017 Q1 | 2.3 Million EUR | 7.94% |
| 2016 Q2 | 2.24 Million EUR | 27.65% |
| 2016 Q3 | 1.44 Million EUR | -35.86% |
| 2016 FY | 6.98 Million EUR | -22.15% |
| 2016 Q1 | 1.76 Million EUR | -57.47% |
| 2016 Q4 | 2.14 Million EUR | 48.49% |
| 2015 Q2 | 2.26 Million EUR | 50.64% |
| 2015 FY | 8.97 Million EUR | 0.14% |
| 2015 Q1 | 1.5 Million EUR | -35.06% |
| 2015 Q4 | 4.13 Million EUR | 92.52% |
| 2015 Q3 | 2.15 Million EUR | -5.12% |
| 2014 FY | 8.95 Million EUR | -54.42% |
| 2014 Q4 | 2.31 Million EUR | 24.47% |
| 2014 Q3 | 1.86 Million EUR | -21.08% |
| 2014 Q2 | 2.35 Million EUR | -23.36% |
| 2014 Q1 | 3.07 Million EUR | -61.84% |
| 2013 Q4 | 8.06 Million EUR | 94.02% |
| 2013 FY | 19.65 Million EUR | -1.77% |
| 2013 Q1 | 4.51 Million EUR | -31.69% |
| 2013 Q2 | 5.28 Million EUR | 17.12% |
| 2013 Q3 | 4.15 Million EUR | -21.41% |
| 2012 FY | 20 Million EUR | 4.77% |
| 2012 Q1 | 4.56 Million EUR | 93.68% |
| 2012 Q2 | 7.22 Million EUR | 58.35% |
| 2012 Q3 | 6.25 Million EUR | -13.39% |
| 2012 Q4 | 6.61 Million EUR | 5.64% |
| 2011 Q1 | 5.63 Million EUR | -4.14% |
| 2011 Q3 | 4.97 Million EUR | -18.97% |
| 2011 Q2 | 6.13 Million EUR | 8.9% |
| 2011 FY | 19.09 Million EUR | -17.38% |
| 2011 Q4 | 2.35 Million EUR | -52.62% |
| 2010 FY | 23.11 Million EUR | 1.08% |
| 2010 Q2 | 6.5 Million EUR | 9.04% |
| 2010 Q3 | 5.67 Million EUR | -12.88% |
| 2010 Q1 | 5.96 Million EUR | -10.52% |
| 2010 Q4 | 5.87 Million EUR | 3.64% |
| 2009 Q4 | 6.67 Million EUR | 18.49% |
| 2009 Q3 | 5.63 Million EUR | 3.88% |
| 2009 Q2 | 5.41 Million EUR | -13.72% |
| 2009 Q1 | 6.28 Million EUR | 0.0% |
| 2009 FY | 22.86 Million EUR | 6.87% |
| 2008 FY | 21.39 Million EUR | 231.81% |
| 2007 FY | -16.23 Million EUR | -52.17% |
| 2006 FY | -10.66 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioNTech SE | 2.52 Billion EUR | 98.9% |
| CureVac N.V. | 211.75 Million EUR | 86.864% |
| Biotest Aktiengesellschaft | 136.8 Million EUR | 79.667% |
| Biotest Aktiengesellschaft | 136.8 Million EUR | 79.667% |
| BRAIN Biotech AG | 24.94 Million EUR | -11.527% |
| Formycon AG | 23.73 Million EUR | -17.203% |
| Medigene AG | 20.54 Million EUR | -35.423% |